Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
暂无分享,去创建一个
Norikazu Masuda | Stephen Chia | Mark Clemons | Carlos L Arteaga | Walter Jonat | Zefei Jiang | Mario Campone | J. Baselga | H. Iwata | W. Jonat | M. Campone | N. Masuda | S. Im | Masato Takahashi | C. Arteaga | S. Chia | M. Clemons | A. Awada | B. Pistilli | M. De Laurentiis | Zefei Jiang | P. Vuylsteke | J. Cortés | A. Jagiełło-Gruszfeld | S. Hurvitz | E. di Tomaso | L. Tseng | C. Massacesi | P. Urban | B. Dharan | José Baselga | Ahmad Awada | Yoshinori Ito | Michele De Laurentiis | Seock-Ah Im | Hiroji Iwata | Javier Cortés | Agnieszka Jagiełło-Gruszfeld | Barbara Pistilli | Ling-Ming Tseng | Sara Hurvitz | Masato Takahashi | Peter Vuylsteke | Soulef Hachemi | Bharani Dharan | Emmanuelle Di Tomaso | Patrick Urban | Cristian Massacesi | Yoshinori Ito | S. Hachemi | M. Takahashi | Bharani Dharan
[1] M. Piccart,et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[3] P. Lønning,et al. Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment , 2017 .
[4] A. Howell,et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. , 2013, The Lancet. Oncology.
[5] W. Sellers,et al. Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.
[6] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[7] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[8] S. Loi,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[9] J. Bendell,et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors , 2014, Investigational New Drugs.
[10] M. Lichinitser,et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Hampton,et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant , 2016, Nature Communications.
[12] Frank Bretz,et al. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures , 2011, Statistics in medicine.
[13] M. Ellis,et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer , 2011, Breast Cancer Research.
[14] M. Berger,et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Charles Swanton,et al. Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.
[16] E. Winer,et al. Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer , 2015 .
[17] Michael G. Kharas,et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.
[18] Obi L. Griffith,et al. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2015, Clinical Cancer Research.
[19] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[21] G. Mills,et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.
[22] Angela Tam,et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. , 2015, Cancer cell.
[23] G. Mills,et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. , 2011, Cancer discovery.
[24] Obi L. Griffith,et al. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.
[25] J. Ware,et al. First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.
[26] Z. Szallasi,et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution , 2015, Science Translational Medicine.
[27] Ben H. Park,et al. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.
[28] W. Yung,et al. Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells , 2011, Clinical Cancer Research.
[29] E. Winer,et al. Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer , 2015 .
[30] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[31] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[32] N. Rosen,et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer , 2013, Science Translational Medicine.
[33] M. Piccart,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] J. Berlin,et al. 451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] Frank Bretz,et al. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests , 2011, Biometrical journal. Biometrische Zeitschrift.